Myokardia

Myokardia company information, Employees & Contact Information

Explore related pages

Related company profiles:

We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease. For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W

Company Details

Employees
29
Founded
-
Address
1000 Sierra Point Parkway, Brisbane,california 94005,united States
Phone
650 741 0900
Email
in****@****dia.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Brisbane, California
Looking for a particular Myokardia employee's phone or email?

Myokardia Questions

News

Trio behind MyoKardia raise $300 million for new biotech firm focused on heart disease - statnews.com

Trio behind MyoKardia raise $300 million for new biotech firm focused on heart disease statnews.com

BMS pushes Fulcrum off its list of partners, scrapping MyoKardia heart muscle pact - Fierce Biotech

BMS pushes Fulcrum off its list of partners, scrapping MyoKardia heart muscle pact Fierce Biotech

Kardigan gets the rights to a MyoKardia drug; Lilly stops Phase 2 trial for muscle-sparing candidate - Endpoints News

Kardigan gets the rights to a MyoKardia drug; Lilly stops Phase 2 trial for muscle-sparing candidate Endpoints News

MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease - BioSpace

MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease BioSpace

Bristol Myers Squibb acquires MyoKardia Inc., a biomedical company co-founded by CU professor - University of Colorado Boulder

Bristol Myers Squibb acquires MyoKardia Inc., a biomedical company co-founded by CU professor University of Colorado Boulder

Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for the heart - BioPharma Dive

Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for the heart BioPharma Dive

Bristol Myers expands heart drug business with $13 bln deal for MyoKardia - Reuters

Bristol Myers expands heart drug business with $13 bln deal for MyoKardia Reuters

Mavacamten Gets Breakthrough Therapy Status for Obstructive Hypertrophic Cardiomyopathy - Medical Professionals Reference

Mavacamten Gets Breakthrough Therapy Status for Obstructive Hypertrophic Cardiomyopathy Medical Professionals Reference

Study Design and Rationale of EXPLORER-HCM: - American Heart Association Journals

Study Design and Rationale of EXPLORER-HCM: American Heart Association Journals

BMS acquires biopharma firm MyoKardia for $13.1bn - Pharmaceutical Technology

BMS acquires biopharma firm MyoKardia for $13.1bn Pharmaceutical Technology

MyoKardia starts dosing hypertrophic cardiomyopathy patients - Clinical Trials Arena

MyoKardia starts dosing hypertrophic cardiomyopathy patients Clinical Trials Arena

BMS to buy MyoKardia, adding heart disease drug for $13.1bn - BioProcess International

BMS to buy MyoKardia, adding heart disease drug for $13.1bn BioProcess International

Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia - PR Newswire

Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia PR Newswire

Bristol Myers Squibb acquires MyoKardia, co-founded by CU Boulder faculty, for $13.1 billion in cash - University of Colorado Boulder

Bristol Myers Squibb acquires MyoKardia, co-founded by CU Boulder faculty, for $13.1 billion in cash University of Colorado Boulder

Bristol Myers strikes $13B MyoKardia buyout to gain heart drug - Fierce Biotech

Bristol Myers strikes $13B MyoKardia buyout to gain heart drug Fierce Biotech

MyoKardia pops as heart drug passes most important test - BioPharma Dive

MyoKardia pops as heart drug passes most important test BioPharma Dive

Results indicate MyoKardia drug is a ‘potential game changer’ for heart condition - statnews.com

Results indicate MyoKardia drug is a ‘potential game changer’ for heart condition statnews.com

BMS Strengthens Cardiovascular Business with $13.1 Billion MyoKardia Buyout - BioSpace

BMS Strengthens Cardiovascular Business with $13.1 Billion MyoKardia Buyout BioSpace

MyoKardia cuts all ties to Sanofi - BioPharma Dive

MyoKardia cuts all ties to Sanofi BioPharma Dive

MyoKardia drug improves blood flow in patients with serious, inherited form of heart disease - statnews.com

MyoKardia drug improves blood flow in patients with serious, inherited form of heart disease statnews.com

BMS to buy MyoKardia for access to late-stage heart disease drug - Chemical & Engineering News

BMS to buy MyoKardia for access to late-stage heart disease drug Chemical & Engineering News

Anatomy of a deal: How MyoKardia got BMS to bump up its buyout to $13B - Fierce Biotech

Anatomy of a deal: How MyoKardia got BMS to bump up its buyout to $13B Fierce Biotech

Bristol to Pay $13.1 Billion for Heart-Drug Maker MyoKardia - The Wall Street Journal

Bristol to Pay $13.1 Billion for Heart-Drug Maker MyoKardia The Wall Street Journal

MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash - markets.businessinsider.com

MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash markets.businessinsider.com

Bristol-Myers to buy heart drugs developer MyoKardia for about $13 billion - CNBC

Bristol-Myers to buy heart drugs developer MyoKardia for about $13 billion CNBC

Bristol-Myers Squibb to Acquire MyoKardia for $13.1B, Expanding Cardiovascular Franchise - Genetic Engineering and Biotechnology News

Bristol-Myers Squibb to Acquire MyoKardia for $13.1B, Expanding Cardiovascular Franchise Genetic Engineering and Biotechnology News

MyoKardia transforms inherited heart disease symptoms in midstage trial - Fierce Biotech

MyoKardia transforms inherited heart disease symptoms in midstage trial Fierce Biotech

Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says - CNBC

Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says CNBC

After 4 years, it’s a no from Sanofi as it punts MyoKardia drug program deal - Fierce Biotech

After 4 years, it’s a no from Sanofi as it punts MyoKardia drug program deal Fierce Biotech

BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B - MedCity News

BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B MedCity News

MyoKardia and Sanofi part ways in collaboration - Drug Discovery News

MyoKardia and Sanofi part ways in collaboration Drug Discovery News

Sanofi ends heart drug collaboration with MyoKardia - BioPharma Dive

Sanofi ends heart drug collaboration with MyoKardia BioPharma Dive

Fulcrum Therapeutics Ends Agreement with MyoKardia - Investing.com

Fulcrum Therapeutics Ends Agreement with MyoKardia Investing.com

Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform - Business Wire

Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform Business Wire

MyoKardia's Experimental HCM Treatment Mavacamten Hits All Primary and Secondary Endpoints in Phase III Study - BioSpace

MyoKardia's Experimental HCM Treatment Mavacamten Hits All Primary and Secondary Endpoints in Phase III Study BioSpace

MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart - BioSpace

MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart BioSpace

Perceptive debuts LianBio with cancer and heart disease programs from BridgeBio, MyoKardia - Fierce Biotech

Perceptive debuts LianBio with cancer and heart disease programs from BridgeBio, MyoKardia Fierce Biotech

MyoKardia Reports Topline Results in Phase 2 Study of Mavacamten - drugdiscoverytrends.com

MyoKardia Reports Topline Results in Phase 2 Study of Mavacamten drugdiscoverytrends.com

BMS to Acquire MyoKardia for $13.1B - Contract Pharma

BMS to Acquire MyoKardia for $13.1B Contract Pharma

Bristol-Myers’ $13 Billion Deal for MyoKardia Spotlights Cardiac Drugs - Barron's

Bristol-Myers’ $13 Billion Deal for MyoKardia Spotlights Cardiac Drugs Barron's

At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis - Endpoints News

At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis Endpoints News

Sanofi opts out of MyoKardia assets - The Pharma Letter

Sanofi opts out of MyoKardia assets The Pharma Letter

MyoKardia Shareholders Are Getting a Really Sweet Payday - 24/7 Wall St.

MyoKardia Shareholders Are Getting a Really Sweet Payday 24/7 Wall St.

Jonathan Fox leaves AstraZeneca for MyoKardia - PMLiVE

Jonathan Fox leaves AstraZeneca for MyoKardia PMLiVE

Top Myokardia Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant